|Bid||279.10 x 100|
|Ask||284.20 x 100|
|Day's Range||280.75 - 284.32|
|52 Week Range||244.28 - 333.65|
|PE Ratio (TTM)||17.63|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We analyzed publicly traded companies based in the Bay State to identify the best stock in Massachusetts to buy now.
A biotech breakout may be fueled by positive medical data and earnings
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.